Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers

<p>Abstract</p> <p>Background</p> <p>Safety and effectiveness of efficacious antiretroviral (ARV) regimens beyond single-dose nevirapine (sdNVP) for prevention of mother-to-child transmission (PMTCT) have been demonstrated in well-controlled clinical studies or in secon...

Full description

Saved in:
Bibliographic Details
Main Authors: Mandala Justin (Author), Torpey Kwasi (Author), Kasonde Prisca (Author), Kabaso Mushota (Author), Dirks Rebecca (Author), Suzuki Chiho (Author), Thompson Catherine (Author), Sangiwa Gloria (Author), Mukadi Ya (Author)
Format: Book
Published: BMC, 2009-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_4d25d3d0f1d84b08a5c23e43d6fb0456
042 |a dc 
100 1 0 |a Mandala Justin  |e author 
700 1 0 |a Torpey Kwasi  |e author 
700 1 0 |a Kasonde Prisca  |e author 
700 1 0 |a Kabaso Mushota  |e author 
700 1 0 |a Dirks Rebecca  |e author 
700 1 0 |a Suzuki Chiho  |e author 
700 1 0 |a Thompson Catherine  |e author 
700 1 0 |a Sangiwa Gloria  |e author 
700 1 0 |a Mukadi Ya  |e author 
245 0 0 |a Prevention of mother-to-child transmission of HIV in Zambia: implementing efficacious ARV regimens in primary health centers 
260 |b BMC,   |c 2009-08-01T00:00:00Z. 
500 |a 10.1186/1471-2458-9-314 
500 |a 1471-2458 
520 |a <p>Abstract</p> <p>Background</p> <p>Safety and effectiveness of efficacious antiretroviral (ARV) regimens beyond single-dose nevirapine (sdNVP) for prevention of mother-to-child transmission (PMTCT) have been demonstrated in well-controlled clinical studies or in secondary- and tertiary-level facilities in developing countries. This paper reports on implementation of and factors associated with efficacious ARV regimens among HIV-positive pregnant women attending antenatal clinics in primary health centers (PHCs) in Zambia.</p> <p>Methods</p> <p>Blood sample taken for CD4 cell count, availability of CD4 count results, type of ARV prophylaxis for mothers, and additional PMTCT service data were collected for HIV-positive pregnant women and newborns who attended 60 PHCs between April 2007 and March 2008.</p> <p>Results</p> <p>Of 14,815 HIV-positive pregnant women registered in the 60 PHCs, 2,528 (17.1%) had their CD4 cells counted; of those, 1,680 (66.5%) had CD4 count results available at PHCs; of those, 796 (47.4%) had CD4 count ≤ 350 cells/mm<sup>3 </sup>and thus were eligible for combination antiretroviral treatment (cART); and of those, 581 (73.0%) were initiated on cART. The proportion of HIV-positive pregnant women whose blood sample was collected for CD4 cell count was positively associated with (1) blood-draw for CD4 count occurring on the same day as determination of HIV-positive status; (2) CD4 results sent back to the health facilities within seven days; (3) facilities <it>without </it>providers trained to offer ART; and (4) urban location of PHC. Initiation of cART among HIV-positive pregnant women was associated with the PHC's capacity to provide care and antiretroviral treatment services. Overall, of the 14,815 HIV-positive pregnant women registered, 10,015 were initiated on any type of ARV regimen: 581 on cART, 3,041 on short course double ARV regimen, and 6,393 on sdNVP.</p> <p>Conclusion</p> <p>Efficacious ARV regimens beyond sdNVP can be implemented in resource-constrained PHCs. The majority (73.0%) of women identified eligible for ART were initiated on cART; however, a minority (11.3%) of HIV-positive pregnant women were assessed for CD4 count and had their test results available. Factors associated with implementation of more efficacious ARV regimens include timing of blood-draw for CD4 count and capacity to initiate cART onsite where PMTCT services were being offered.</p> 
546 |a EN 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n BMC Public Health, Vol 9, Iss 1, p 314 (2009) 
787 0 |n http://www.biomedcentral.com/1471-2458/9/314 
787 0 |n https://doaj.org/toc/1471-2458 
856 4 1 |u https://doaj.org/article/4d25d3d0f1d84b08a5c23e43d6fb0456  |z Connect to this object online.